EMA’s decision takes into account data presented by the pharmacist that show an increase in antibody production when the booster dose is applied six months after the second
A European Medicines Agency (EMA) recommended the application of third dose of the vaccine Pfizer against a Covid-19 in adults. A decision by the Committee for Medicines for Human Use (CHMP) taken this Monday, 4, concluded that the third dose can be applied to people over 18 six months after the application of the second dose. The decision was made based on data presented by Pfizer that show an increase in the level of antibody production when the booster dose is applied six months after the second. Despite approving, the EMA stated that the use of the extra dose must be authorized by national bodies taking into account internal factors such as the progress of the vaccination campaign and availability of immunizing agents. “The risk of inflammatory heart disease or other very rare side effects after a booster dose is not known and is being carefully monitored,” noted the EMA, which said it will continue to look at the effectiveness of vaccines and drugs.
*With information from EFE